Please login to the form below

Not currently logged in
Email:
Password:

Astellas purchases OSI

Japanese company Astellas Pharma has announced that it has completed the acquisition of US biotech, OSI Pharmaceuticals

Japan's second largest pharma company, Astellas Pharma, has announced that it has completed the acquisition of US biotech OSI Pharmaceuticals through a short-form merger.

In the deal, valued at $4bn, each outstanding share of OSI common stock not purchased in Astellas' tender offer, or otherwise owned by Astellas, was converted into the right to receive the same amount of $57.50. This is 11 per cent more than a previously proposed $52 per share.

OSI is now a wholly-owned subsidiary of Astellas US Holdings, which is owned by Astellas Pharma. The acquisition marks the completion of a hostile takeover bid launched in March this year after Astellas originally initiated talks with OSI in early 2009 and adds cancer blockbuster, Tarceva (erlotinib) to Astellas' portfolio.

Masafumi Nogimori, president and CEO of Astellas, said: "This compelling transaction marks an important step forward for Astellas as the company works towards developing a world-class oncology platform."

OSI is a biotechnology company focused on the discovery, development and commercialisation of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity. Tarceva is the company's lead cancer drug, with several other drug prospects in the R&D pipeline.

The purchase of OSI will bolster Astellas' existing interests in urology and transplantation as its urinary drug, Flomax (tamsulosin), and transplant drug, Prograf (tacrolimus), recently lost patent protection in the US and face generic competition.

It also takes Astellas into the US market after its hostile bid for CV Therapeutics failed last year.

9th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics